Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 known ✓ | P22748 | 4/20 | 0.52 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.48 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27742460 | 0.97 | CA4 (0.50) | CA4CA2CTSLCASP1SLC22A16 | |
| Potassium Ion SCHEMBL31206140 | 0.95 | CA4 (0.48) | CA4CA2CTSLCASP1SLC22A16 | |
| SCHEMBL1546186 | 0.94 | CA4 (0.48) | CA4CA2CTSLCASP1SLC22A16 | |
| SCHEMBL29199237 | 0.94 | CA4 (0.48) | CA4CA2CTSLCASP1SLC22A16 | |
| SCHEMBL7899819 | 0.94 | CTSL (0.50) | CA4CA2CTSLCASP1SLC22A16 | |
| Silver SCHEMBL6741767 | 0.94 | CA4 (0.48) | CA4CA2CTSLCASP1SLC22A16 | |
| Potassium Ion SCHEMBL637500 | 0.94 | CA4 (0.48) | CA4CA2CTSLCASP1SLC22A16 | |
| SCHEMBL6741776 | 0.94 | CA4 (0.48) | CA4CA2CTSLCASP1SLC22A16 | |
| Lithium Ion SCHEMBL29028816 | 0.94 | CA4 (0.48) | CA4CA2CTSLCASP1SLC22A16 | |
| Zinc Ion SCHEMBL6051610 | 0.94 | CA4 (0.48) | CA4CA2CTSLCASP1SLC22A16 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113322225-A | Additive for human embryonic stem cell in vitro amplification and amplification method | 郑州优倍得生物科技有限公司 | 2021-08-31 | — | — | CN | claimed |
| JP-55073350-A | — | — | None | — | — | JP | disclosed |
| US-20260070068-A1 | AMMONIATED POLYCARBAMIDE SEPARATION AIDS FOR MINERAL FLOTATION | HEXION INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-11578327-B2 | Oligonucleotide therapy for Wilson disease | DEEP GENOMICS INCORPORATED (CA) | 2023-02-14 | — | — | US | disclosed |
| CN-113322225-A | Additive for human embryonic stem cell in vitro amplification and amplification method | 郑州优倍得生物科技有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-113322225-A | Additive for human embryonic stem cell in vitro amplification and amplification method | 郑州优倍得生物科技有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20210032629-A1 | OLIGONUCLEOTIDE THERAPY FOR WILSON DISEASE | DEEP GENOMICS INCORPORATED (CA) | 2021-02-04 | — | — | US | disclosed |
| EP-3752614-A1 | OLIGONUCLEOTIDE THERAPY FOR WILSON DISEASE | Deep Genomics Incorporated (CA) | 2020-12-23 | — | — | EP | disclosed |
| CN-112041439-A | Oligonucleotide therapy for wilson's disease | 深度基因组学公司 | 2020-12-04 | — | — | CN | disclosed |
| WO-2020045454-A1 | RUBBER COMPOSITION, METAL-RUBBER COMPOSITE MOLDED BODY AND METHOD FOR PRODUCING METAL-RUBBER COMPOSITE MOLDED BODY | 住友化学株式会社 | 2020-03-05 | — | — | WO | disclosed |
| US-20090110889-A1 | CONDUCTIVE PATTERN FORMATION INK, CONDUCTIVE PATTERN AND WIRING SUBSTRATE | SEIKO EPSON CORPORATION (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090090272-A1 | CONDUCTIVE PATTERN FORMATION INK, CONDUCTIVE PATTERN AND WIRING SUBSTRATE | SEIKO EPSON CORPORATION (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090087580-A1 | INK COMPOSITION, PATTERN FORMATION METHOD AND DROPLET DISCHARGE DEVICE | SEIKO EPSON CORPORATION (JP) | 2009-04-02 | — | — | US | disclosed |
| US-7367999-B2 | Ultrafine particles and method and apparatus for producing the same | FUJIFILM CORPORATION (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050126340-A1 | Ultrafine particles and method and apparatus for producing the same | FUJI PHOTO FILM CO., LTD. | 2005-06-16 | — | — | US | disclosed |
| US-20030019327-A1 | Ultrafine particles and method and apparatus for producing the same | FUJI PHOTO FILM CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| US-4622131-A | DEPRESSANT BLEND | PHILLIPS PETROLEUM COMPANY (US) | 1986-11-11 | — | — | US | disclosed |
| US-4533466-A | FOR MINERAL RECOVERY USING FROTH FLOTATION | PHILLIPS PETROLEUM COMPANY (US) | 1985-08-06 | — | — | US | disclosed |
| US-4482480-A | ORE FLOATION AGENTS, TRITHIONCARBONATE DERIVATIVES | PHILLIPS PETROLEUM COMPANY (US) | 1984-11-13 | — | — | US | disclosed |
| JP-S5573350-A | DETERGENT FOR ION EXCHANGE RESIN | NITTO KAKO KK | 1980-06-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070068-A1 | AMMONIATED POLYCARBAMIDE SEPARATION AIDS FOR MINERAL FLOTATION | FOS, SETD1A, SETDB1 | CA4 1570/4885CA2 1352/4885CA1 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.